Linda Louie biography
Linda H. Louie serves as Vice President - Finance, Chief Accounting Officer of the Company. Ms. Louie previously served as the Company’s Executive Director, Accounting since June 2015 and was a Director of Finance at the Company from April 2011 to June 2015. From June 2000 until April 2011, Ms. Louie progressed through various positions of increasing responsibility at the Company. She is a Certified Public Accountant and received her Master of Business Administration from the Fuqua School of Business at Duke University.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Linda Louie?
Linda Louie is 48, she's been the Vice President - Finance e Chief Accounting Officer of AMGEN since 2020. There are 26 older and no younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
What's Linda Louie's mailing address?
Linda's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320.
Insiders trading at AMGEN
Over the last 22 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer, eEllen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
What does AMGEN do?
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
What does AMGEN's logo look like?
AMGEN executives and stock owners
AMGEN executives and other stock owners filed with the SEC include:
-
Robert Bradway,
Chairman of the Board, President, Chief Executive Officer -
Jonathan Graham,
Senior Vice President, General Counsel, Secretary -
Murdo Gordon,
Executive Vice President of Global Commercial Operations -
David Reese,
Executive Vice President - Research and Development -
Robert A. Bradway,
Chairman, CEO & Pres -
Murdo Gordon,
Exec. VP of Global Commercial Operations -
Dr. David M. Reese M.D.,
Exec. VP of R&D -
Esteban Santos,
Exec. VP of Operations -
Peter H. Griffith,
Exec. VP & CFO -
Robert Eckert,
Lead Independent Director -
Gregory Garland,
Independent Director -
Ronald Sugar,
Independent Director -
Charles Holley,
Independent Director -
Wanda Austin,
Independent Director -
Brian Druker,
Independent Director -
Fred Hassan,
Independent Director -
Robert Williams,
Independent Director -
Tyler Jacks,
Independent Director -
Ellen Kullman,
Independent Director -
Amy Miles,
Independent Director -
Linda Louie,
Vice President - Finance, Chief Accounting Officer -
David Piacquad,
Senior Vice President - Business Development -
Lori Johnston,
Senior Vice President - Human Resources -
Cynthia Patton,
Senior Vice President, Chief Compliance Officer -
Esteban Santos,
Executive Vice President, Operations -
Peter Griffith,
Chief Financial Officer, Executive Vice President -
Nancy A. Grygiel,
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer -
Jonathan P. Graham,
Exec. VP, Gen. Counsel & Sec. -
Arvind Sood,
VP of Investor Relations -
Mike Zahigian,
Sr. VP & Chief Information Officer -
Linda H. Louie,
VP of Fin. & Chief Accounting Officer -
Annette Louise Such,
CAO -
Frank Biondi,
Director -
Greg C. Garland,
Director -
Frank C Herringer,
Director -
David W Meline,
EVP & CFO -
Anthony C Hooper,
EVP, Global Commercial Ops. -
R Sanders Williams,
Director -
Rebecca M Henderson,
Director -
Judith C Pelham,
Director -
David Baltimore,
Director -
Sean E Harper,
EVP, Research & Development -
Carbonnel Francois De,
Director -
James E. Bradner,
EVP, R&D, & Chief Sci. Officer -
Nancy A. Grygiel,
SVP & CCO -
Thomas James Flanagan,
Sr VP & CIO -
Leonard D Schaeffer,
Director -
Jonathan M Peacock,
CFO -
Gilbert S Omenn,
Director -
J Paul Reason,
Director -
Thomas J.W. Dittrich,
VP, Finance & CAO -
David J Scott,
Sr. VP, Gen. Counsel & Secy. -
A Kelly Michael,
VP Corp Plng & Control & CAO -
Stuart A Tross,
SVP, Human Resources -
Kevin W Sharer,
Chairman of the Bd, CEO & Pres -
Vance D Coffman,
Director -
David W Beier,
SVP Global Govt & Corp Affairs -
Fabrizio Bonanni,
Senior VP, Manufacturing -
Anna Richo,
SVP & CCO -
Jerry D Choate,
Director -
Frederick W Gluck,
Director -
Roger M Perlmutter,
Exec VP Research & Development -
George J Morrow,
Exe VP, Global Commercial Ops -
Brian M Mcnamee,
Sr. V.P. Human Resources -
Richard D Nanula,
Exe VP Fin, Strat & Comm & CFO -
Franklin P Jr Johnson,
Director -
Donald B Rice,
Director -
Dennis M Fenton,
Executive Vice President -
Hassan Dayem,
Sr. V.P. & Chief Info. Officer -
Barry D Schehr,
VP Financial Ops & CAO -
Edward V Fritzky,
Director -
Steven M Odre,
Sr. VP, Gen. Cousel & Secy. -
Timothy O Martin,
V.P., Planning and Control -
Beth C Seidenberg,
Sr VP Development -
Willard H Dere,
Sr. V.P., Global Dev & CMO -
Joseph P Miletich,
Sr VP Rsch & Preclinical Dev -
Patricia C Sueltz,
Director -
Steven Lazarus,
Director -
Derek Miller,
SVP, Human Resources -
Omar Ishrak,
Director -
Rachna Khosla,
SVP, Business Development -
Michael V Drake,
Director -
Matthew C. Busch,
VP, Finance & CAO -
Mary E. Klotman,
Director